GAMMA Investing LLC Has $28,000 Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

GAMMA Investing LLC raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 297.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,175 shares of the biotechnology company’s stock after purchasing an additional 1,628 shares during the period. GAMMA Investing LLC’s holdings in Arrowhead Pharmaceuticals were worth $28,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Xponance Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 4.5% in the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock worth $327,000 after acquiring an additional 744 shares during the last quarter. Summit Investment Advisors Inc. grew its position in Arrowhead Pharmaceuticals by 2.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock worth $714,000 after purchasing an additional 803 shares during the last quarter. ADAR1 Capital Management LLC grew its position in Arrowhead Pharmaceuticals by 10.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 1,195 shares during the last quarter. Swiss National Bank grew its position in Arrowhead Pharmaceuticals by 0.8% in the 4th quarter. Swiss National Bank now owns 220,000 shares of the biotechnology company’s stock worth $4,136,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Bank of Montreal Can grew its position in Arrowhead Pharmaceuticals by 13.3% in the 4th quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company’s stock worth $282,000 after purchasing an additional 1,759 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ARWR shares. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Wall Street Zen raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Finally, Citigroup decreased their price target on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $18.31 on Friday. The stock’s fifty day simple moving average is $15.87 and its 200 day simple moving average is $16.38. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.15 and a quick ratio of 5.15. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of -13.08, a P/E/G ratio of 22.18 and a beta of 0.93. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the firm posted ($1.02) EPS. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.